Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Neurotrope, Inc. (NASDAQ: NTRP).

Full DD Report for NTRP

You must become a subscriber to view this report.


Recent News from (NASDAQ: NTRP)

Alzheimer's Pathways: An Investor's Guide To Biogen, Anavex, And Neurotrope
At the recent CTAD conference in Barcelona, Spain a number of companies presented new data regarding their Alzheimer’s drug candidates. Much of the attention focused on Biogen ( BIIB ), but other companies may be pursuing more fruitful strategies against Alzheimer’s disease. In...
Source: SeekingAlpha
Date: November, 06 2018 10:42
Neurotrope to Present at the Ladenburg Thalmann 2018 Healthcare Conference
NEW YORK , Sept. 27, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced that Dr. Charles Ryan , Neurotrope's Chief Execut...
Source: PR Newswire
Date: September, 27 2018 08:30
Neurotrope Enters into Collaboration with the Nemours / Alfred I. duPont Hospital for Children to Initiate a Clinical Trial in Fragile X Syndrome
NEW YORK , Sept. 5, 2018 /PRNewswire/ -- Neurotrope Inc. (NASDAQ: NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease (AD), is announcing a collaboration with The Nemours / Alfred...
Source: PR Newswire
Date: September, 05 2018 08:30
Neurotrope Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018
NEW YORK , Aug. 28, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced it will be featured as a presenting company at the 20 th ...
Source: PR Newswire
Date: August, 28 2018 08:30
Neurotrope EPS of -$0.27
Neurotrope (NASDAQ: NTRP ): Q2 EPS of -$0.27 may not be comparable to consensus of -$0.42. More news on: Neurotrope, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 13 2018 08:37
Neurotrope Provides Business Update and Reports Second Quarter 2018 Financial Results
NEW YORK , Aug. 13, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today provided a business update outlining recent clinical development progre...
Source: PR Newswire
Date: August, 13 2018 08:30
At AAIC 2018, Neurotrope Presents Additional Clinical Results Showing Cognitive Improvement in Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients
NEW YORK , July 25, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) today presented additional clinical results from its recently completed Phase 2 trial demonstrating that moderate-to-severe Alzheimer's disease (AD) patients treated with 20 µg Bryostatin-1 showed evidence ...
Source: PR Newswire
Date: July, 25 2018 08:30
Neurotrope Announces the Initiation of Enrollment of its Confirmatory Phase 2 Trial in Alzheimer's Disease
NEW YORK , July 16, 2018 /PRNewswire/ -- Neurotrope Inc. (NASDAQ: NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing that the first patient has been enrolled into its ...
Source: PR Newswire
Date: July, 16 2018 08:30
Neurotrope Appoints Leading Experts in Alzheimer's Disease to its Scientific Advisory Board (SAB)
NEW YORK , July 11, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing that it has established its Scientific Advisory Board (SAB...
Source: PR Newswire
Date: July, 11 2018 08:30
Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting
NEW YORK , July 2, 2018 /PRNewswire/ -- Neurotrope Inc. (NASDAQ: NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing  the acceptance of a presentation at the Alzheimer's Ass...
Source: PR Newswire
Date: July, 02 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-089.359.359.358.90117,185
2018-05-189.019.199.468.9171,706
2018-05-179.019.199.468.9171,706

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1741,20843,97793.7035Short
2018-12-148,6868,78698.8618Short
2018-12-1311,10613,46782.4683Short
2018-12-1217,32139,66643.6671Short
2018-12-111,9842,23488.8093Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NTRP.


About Neurotrope, Inc. (NASDAQ: NTRP)

Logo for Neurotrope, Inc. (NASDAQ: NTRP)

lt p gt Neurotrope BioScience, Inc. is a specialty biopharmaceutical company developing new therapeutics for the treatment of rare diseases Orphan diseases and Alzheimers Disease. NTRP has also advanced two other Orphan Disease programs using Bryostatin. We are working with the Ichan School of Medicine at Mt. Sinai Hospital in New York to determine the efficacy of Bryostatin for the treatment of Niemann Pick Disease, Type C. In addition, we are also working with the FRAXA Research Foundation to help find a treatment for Fragile X Syndrome using Bryostatin . NTRP licensed the use of Bryostatin for the treatment of Alzheimers Disease as well as other neurodegenerative diseases from the Blanchette Rockefeller Neuroscience Institute BRNI . To date NTRP has successfully completed a first Phase study in moderate Alzheimers patients. We are now conducting a second Phase study. NTRP has also teamed up with Stanford University to find the next generation Bryostatin Bryologs. lt /p gt

 

 

 

Current Management

  • Susanne Wilke / CEO
  • Daniel Alkon / President
    • Dr. Alkon was appointed as our President on September , . Dr. Alkon served as the founding Scientific Director of CRE from until September , . He received his undergraduate degree in chemistry in at the University of Pennsylvania. After earning his M.D. at Cornell University and finishing an internship in medicine at the Mount Sinai Hospital in New York, he joined the staff of the National Institutes of Health where during his year career he became a Medical Director in the U.S. Public Health Service at the National Institute for Neurological Disorders and Strokes and Chief of the Laboratory of Adaptive Systems. From June to September , , Dr. Alkon was the Toyota Chair for Neurodegenerative Disease Research at CRE. In this position, he and his team conducted multidisciplinary research on the molecular and biophysical mechanisms of memory and memory dysfunction in psychiatric and neurological disorders, particularly AD. From October to September , , Dr. Alkon was also a Professor at CRE and a Professor of Neurology at West Virginia University.
  • Robert Weinstein / CFO, Corporate Secretary, EVP
    • Mr. Weinstein joined the Company in June as its acting Chief Financial Officer. He has extensive accounting and finance experience, spanning more than years, as a public accountant, investment banker, healthcare private equity fund principal and chief financial officer. From September to current, Mr. Weinstein has been an independent consultant for several healthcare companies in the pharmaceutical and biotechnology industries. From March to August , he was the Chief Financial Officer of Green Energy Management Services Holdings, Inc., a publiclytraded energy consulting company. From August to February , Mr. Weinstein served as Chief Financial Officer of Xcorporeal, Inc., a publiclytraded, developmentstage medical device company which was sold in March to Fresenius Medical USA, the largest provider of dialysis equipment and services worldwide. Mr. Weinstein received his MBA degree in finance and international business from the University of Chicago Graduate School of Business, is a Certified Public Accountant inactive , and received his BS degree in accounting from the State University of New York at Albany.
  • Paul E. Freiman / Chairman
  • Kenneth J. Gorelick /
  • James Gottlieb /
  • Shana Phares /
  • Joshua Silverman /
  • William Singer /
  • Susanne Wilke /

Current Share Structure

  • Market Cap: $65,790,625 - 03/15/2018
  • Authorized: 12,500,000 - 01/12/2017
  • Issue and Outstanding: 7,907,527 - 02/28/2018
  • Float: 1,627,372 - 01/12/2017

 


Recent Filings from (NASDAQ: NTRP)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 08 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 06 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 06 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 08 2018

 

 


Daily Technical Chart for (NASDAQ: NTRP)

Daily Technical Chart for (NASDAQ: NTRP)


Stay tuned for daily updates and more on (NASDAQ: NTRP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NTRP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NTRP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NTRP and does not buy, sell, or trade any shares of NTRP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/